Pharmaceutical Product Development Stock To Go Ex-dividend Tomorrow (PPDI)
The ex-dividend date for Pharmaceutical Product Development (Nasdaq:PPDI) is tomorrow, September 13, 2011. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $29.98 as of 9:30 a.m., the dividend yield is 2%.
NEW YORK ( TheStreet) -- The ex-dividend date for Pharmaceutical Product Development (Nasdaq: PPDI) is tomorrow, September 13, 2011. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $29.98 as of 9:30 a.m. ET, the dividend yield is 2%. The average volume for Pharmaceutical Product Development has been 1.3 million shares per day over the past 30 days. Pharmaceutical Product Development has a market cap of $3.4 billion and is part of the health care sector and health services industry. Shares are up 13.9% year to date as of the close of trading on Friday. Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Clinical Development Services and Laboratory Services. The company has a P/E ratio of 47.2, above the average health services industry P/E ratio of 20.7 and above the S&P 500 P/E ratio of 17.7.
Practice your dividend trading strategies and win cash in our stock game.
TheStreet Ratings rates Pharmaceutical Product Development as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pharmaceutical Product Development Ratings Report. See our dividend calendar or top-yielding stocks list.
Pharmaceutical Product Development (Nasdaq:PPDI) hit a new 52-week high Monday as it is currently trading at $33.12, above its previous 52-week high of $33.09 with 3.3 million shares traded as of four p.m. ET. Average volume has been 2.9 million shares over the past 30 days.